In the present study of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) treated with percutaneous Background-Prasugrel and ticagrelor provide a superior anti-ischemic action than clopidogrel, with some of ticagrelor's benefits possibly attributed to adenosine-mediated mechanisms. We aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on coronary blood flow velocity (CBFV) during increasing doses of intravenously administered adenosine. Methods and Results-In a prospective, single-center, single-blind, crossover study, 56 patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention were randomized to receive either ticagrelor 90 mg BID or prasugrel 10 mg OD with a 15-day treatment period. At the end of each treatment period, CBFV by transthoracic Doppler echocardiography was assessed at baseline and under incremental doses (50 μg/kg per minute, 80 μg/kg per minute, 110 μg/kg per minute, and 140 μg/kg per minute) of adenosine infusion. Maximal CBFV area under the curve was higher for ticagrelor-treated than for prasugrel-treated patients, with a least squares mean difference of 7.16 (95% confidence interval, 2.61-11.7; P=0.003). Maximal CBFV/baseline CBFV ratio was higher with ticagrelor than prasugrel at 50, 80, and 110 μg/ kg per minute but not at 140 μg/kg per minute adenosine infusion rate, with mean difference ( 
I
n the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with PrasugrelThrombolysis in Myocardial Infarction (TRITON-TIMI) 38, prasugrel provided a better anti-ischemic action than clopidogrel. 1 Furthermore, in the Platelet Inhibition and Patient Outcomes (PLATO) study, ticagrelor reduced the primary end point of death from vascular causes, myocardial infarction, and stroke, along with the secondary end point of death from any cause, compared with clopidogrel. 2 It has been postulated that some of the clinical benefits and side effects, such as dyspnea and asymptomatic ventricular pauses, more frequently observed with ticagrelor are mediated by adenosine. 3, 4 Ticagrelor increases adenosine concentrations by inhibiting red blood cell reuptake 5 and induces ATP release from human red blood cells, which is further degraded to adenosine. 6 In a canine model, ticagrelor and dipyridamole augmented reactive hyperemia in a dose-dependent manner after left anterior descending coronary artery (LAD) occlusion and intracoronary adenosine-induced increases in LAD blood flow. 5 In a study of 40 healthy male volunteers, ticagrelor loading with 180 mg augmented the adenosine-induced increase in the LAD coronary blood flow velocity (CBFV) as assessed by transthoracic Doppler echocardiography. coronary intervention (PCI), we aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on CBFV as assessed by transthoracic Doppler echocardiography under incremental doses of adenosine infusion.
Methods

Study Protocol
We performed a prospective, single-center, single-blind, investigator-initiated, randomized, crossover study to compare the effect of ticagrelor versus prasugrel on adenosine-induced CBFV responses. Consecutive patients aged 18 to 75 years with NSTE-ACS undergoing PCI with drug-eluting stent implantation were included. Patients admitted with ST-elevation myocardial infarction were excluded to avoid possible influence of the infarcted myocardium and left ventricular remodeling to CBFV. 8 Other exclusion criteria were prior myocardial infarction, prior PCI, coronary artery bypass grafting, nonsinus rhythm, requiring hemodialysis, major periprocedural complications or suboptimal PCI result (residual stenosis >20% by visual assessment), contraindication for ticagrelor or prasugrel administration, weight <60 kg, age ≥75 years, risk for bleeding or bradycardic events, severe chronic obstructive pulmonary disease, requirement for oral anticoagulant, left ventricular ejection fraction <45%, left ventricular hypertrophy, diastolic dysfunction, severe valvular disease, any residual LAD stenosis >40% by visual assessment, and diffuse coronary atherosclerosis. Between February 2012 and September 2012, 65 eligible patients were screened 24 to 36 hours after PCI for participation in the study. In 4 (6.2%) patients, baseline LAD CBFV assessment could not be adequately obtained, whereas 5 patients refused to participate in the study. The remaining 56 patients were randomized (day 0) in a 1:1 ratio, using computerized random-number generation by an independent investigator, to receive either ticagrelor 90 mg BID (N=28) or prasugrel 10 mg OD (N=28) for 15 days after randomization, as shown in the study flow chart (Figure 1) . A day 15 visit (visit 1) was performed to evaluate the adenosine-induced CBFV response (see below). Patient compliance with antiplatelet treatment was assessed by interview and tablet counting. Any adverse reactions related to the antiplatelet therapy or the adenosine infusions were documented by an independent observer. A crossover directly to the alternate treatment without washout period was performed, and at day 30 (visit 2) the same evaluation was applied. Patients were instructed to receive their treatment of ticagrelor/prasugrel on the predefined time daily (10:00 am for prasugrel and 10:00 am/10:00 pm for ticagrelor) and to avoid coffee or alcohol consumption, smoking, and exercise for 24 hours before each visit. Discharge medication was kept constant across both study periods.
Adenosine-Induced CBFV Changes
Noninvasive assessment of CBFV by transthoracic Doppler echocardiography 9 was performed by 1 experienced echocardiographer (N.K.) who was blind to treatment allocation. All echocardiographic studies were performed between 1:00 and 3:00 pm after a 3-hour fasting period. Resting pulse and blood pressure were measured, with the patient remaining in a quiet, air-conditioned room (temperature between 20°C and 23°C). After 10 minutes of resting, echocardiography was performed with the patient in the left lateral decubitus position. After the completion of the standard echocardiographic examination, LAD flow was detected using a 4 to 6.7 MHz or a 1.7 to 3.4 MHz multifrequency transducer (GE-Vingmed VIVID 7, Norway). A modified apical 2-chamber view was used, and the flow signal was located by color flow mapping as flow toward the transducer containing a dominant diastolic signal. Care was taken to 
WHAT IS KNOWN
• Compared with clopidogrel, prasugrel and ticagrelor have been shown to decrease ischemic events.
• Some of ticagrelor's benefits have been possibly attributed to adenosine-mediated mechanisms.
• In healthy male volunteers, ticagrelor loading augments the adenosine-induced increase in coronary blood flow velocity.
WHAT THE STUDY ADDS
• In non-ST-segment-elevation acute coronary syndrome patients treated with percutaneous coronary intervention and receiving a maintenance dose of ticagrelor, coronary blood flow velocity augments to a greater degree compared with patients on a prasugrel maintenance dose in response to increasing adenosine concentrations.
• Although exploratory, these findings may represent a pleiotropic action of ticagrelor potentially associated with some of the clinical benefits provided by this agent. avoid interference of myocardial velocity or pericardial motion. The sample volume size was set at 3 mm. The sampling of the flow by pulsed wave Doppler was obtained as parallel as possible to LAD flow (<20°) to avoid underestimation of the peak velocities, and the theta angle was not corrected. Recordings were made at baseline and under 2-minute adenosine intravenous administration at incremental doses of 50, 80, 110, and 140 μg/kg per minute, with 5-minute interval between infusions. For the accurate calculation of the adenosine infusion rate, the patients were weighed before each visit. Blood pressure and heart rate were monitored during the whole examination.
CBFV in the LAD was measured at baseline (bCBFV) and at peak hyperemic conditions (maxCBFV) from spectral Doppler signals using the software incorporated in the ultrasound system. The average of 3 cycles for bCBFV and the maximal (out of ≥25 cardiac cycles) CBFV observed during each 2-minute adenosine infusion were used for calculation of maxCBFV. To evaluate operator's reproducibility, a subgroup of 20 randomly selected patients underwent bCBFV assessment twice on the same day (day 15) by the same examiner (N.K.), 5 minutes apart. Reproducibility was assessed with offline data analysis by an independent physician.
End Points
End points were prespecified in the study protocol and statistical analysis plan. The primary end point was the area under the curve of the LAD maxCBFV at gradually increasing doses of adenosine at the end of the 2 treatment periods. Secondary end points were the ratio of LAD maxCBFV/bCBFV at the end of the 2 treatment periods separately for 50, 80, 110, and 140 μg/kg per minute adenosine infusion rate. A non-prespecified analysis of LAD maxCBFV at the end of the 2 treatment periods separately for 50, 80, 110, and 140 μg/kg per minute adenosine infusion rate was also performed.
Sample Size Calculation
Based on pilot data analysis, we hypothesized that ticagrelor would result in an area under the curve difference of 7.0 compared with prasugrel (with the assumption that the within-patient SD of the response variable would be 11.2). Choosing a power of 85% and a 2-sided α-level of 0.05, ≥48 patients in total were required to reach statistical significance based on the above assumptions.
Statistical Analysis
Categorical data are presented as frequencies and group percentages and continuous data as means±SD. Two-sample t test and the Fisher exact test were used for comparison of continuous and categorical data, respectively. Only patients who successfully completed ≥1 period of the study were considered for analysis.
Individual area under the curves at the end of each treatment period were calculated with the trapezoidal rule and then a mixed linear model was fitted, adjusting for period, treatment sequence (carryover), and treatment effect (fixed factors), with patient indicator as random intercept. Least squares estimates of the mean difference are presented, with 95% confidence interval (CI) and a 2-sided P value for the treatment effect. Secondary end points and the double product (heart rate×systolic blood pressure) were analyzed with mixed effects models fitted separately for each dose of adenosine infusion, with patient as a random intercept and period, sequence, and treatment as fixed effects. Operator's reproducibility was evaluated by using both a linear regression analysis and the Bland-Altman method for assessing the limits of agreement between the repeated measurements. 10 All tests were 2-tailed, and statistical significance was considered for P<0.05. Analyses were performed using SPSS for Windows (version 16.0 SPSS Inc, Chicago, IL) and GraphPad Prism v.5 (GraphPad Software, Inc). The study conforms to the Declaration of Helsinki and was approved by the ethics committee of the University Hospital of Patras, Greece. All patients gave written informed consent for participation.
Results
There were no differences in demographic and clinical characteristics of randomized patients between the 2 groups (Table 1) . Transthoracic Doppler echocardiography images demonstrating LAD bCBFV and maxCBFV at 110 μg/kg per minute adenosine infusion rate recorded in the same patient at day 15 while under prasugrel (A, B) and at day 30 while under ticagrelor (C, D) and the corresponding CBFV ratios are shown in Figure 2A -2D. The primary end point of the LAD maxCBFV area under the curve at gradually increasing doses of adenosine at the end of the 2 treatment periods was higher for ticagrelor-treated than for prasugrel-treated patients, with a least squares mean difference of 7.16 (95% CI, 2.61-11.7; P=0.003; Figure 3 ). The ratio of LAD maxCBFV/bCBFV combined at the end of the 2 treatment periods separately for 50, 80, 110, and 140 μg/ kg per minute adenosine infusion rate is depicted in Table 2 . A significantly higher ratio of LAD maxCBFV/bCBFV was found for ticagrelor compared with prasugrel at 50, 80, and 110 μg/kg per minute adenosine infusion rate. The LAD maxCBFV/bCBFV ratio (coronary flow reserve) at 140 μg/kg per minute adenosine infusion rate did not differ significantly between the 2 agents.
bCBFV did not differ between the 2 groups (Table 3) . LAD maxCBFV combined at the end of treatment periods are shown in Table 3 . A significantly higher LAD maxCBFV was found for ticagrelor compared with prasugrel at 50, 80, and 110 μg/kg per minute adenosine infusion rate. The difference in LAD maxCBFV between the 2 agents was not significant at 140 μg/kg per minute adenosine infusion rate.
At rest, mean arterial pressure (mm Hg) and heart rate (bpm) did not differ between ticagrelor-and prasugrel-treated patients: least squares estimate of the mean difference (95% CI) 95.4 (91.2-99.5), 66.0 (63.5-68.5) and 95.5 (91.3-99.6), 66.0 (63.5-68.5), with P=0.96 and P=0.2, respectively. At peak hyperemia, mean arterial pressure and heart rate did not differ between ticagrelor-and prasugrel-treated patients: Table 4 . Double product was higher at 80 and 110 μg/kg per minute adenosine infusion rates (although with marginal statistical significance at the latter) while on ticagrelor than in prasugrel maintenance dose.
No major bleedings or major adverse cardiovascular events occurred in either treatment group. In total, 19 (33.9%) patients reported a BARC-1 bleeding event (4, 9, and 6 while under ticagrelor, prasugrel, and both treatment periods, respectively) and 2 (3.6%) a BARC-2 bleeding event (both under ticagrelor). Mild-to-moderate dyspnea not leading to study drug discontinuation occurred in 14 (25%) patients while receiving ticagrelor. Asymptomatic, transient, seconddegree atrioventricular block during adenosine infusions, which resolved spontaneously without need for any medical treatment, was observed in 2 patients, both under ticagrelor.
Discussion
In patients with NSTE-ACS undergoing PCI, the noninvasively assessed CBFV was enhanced to a higher degree by ticagrelor compared with prasugrel maintenance dose after intravenous administration of incremental adenosine doses. A previous effort to demonstrate a possible pleiotropic-anti-inflammatory-action of ticagrelor by comparing it with clopidogrel in the Dose Confirmation Study Assessing Anti-Platelet Effects of AZD6140 vs Clopidogrel in NSTEMI 2 (DISPERSE 2) did not succeed. Ticagrelor and clopidogrel seemed not to differ in their effects on the inflammatory biomarkers C-reactive protein, interleukin 6, myeloperoxidase, and soluble CD40 ligand. 11 The differential action of ticagrelor compared with prasugrel on CBFV may represent the first demonstration of a possible ticagrelor's pleiotropic effect in patients with NSTE-ACS.
In a randomized, double-blind, placebo-controlled, crossover study in 40 healthy male volunteers, a single loading dose with 180 mg of ticagrelor resulted in augmentation of the adenosine-induced (at doses of 50 and 80 μg/kg per minute) increase in the LAD CBFV at 2 hours after the loading dose. 7 Our study, using similar methodology-Doppler echocardiography-in patients with NSTE-ACS demonstrated a higher LAD CBFV up to the 110 μg/kg per minute adenosine infusion rate while on maintenance treatment of ticagrelor compared with prasugrel. We used prasugrel as a comparator to ticagrelor because, to our knowledge, no possibility has been raised that prasugrel may have any off-target action, while it would be unethical to test ticagrelor against placebo.
Findings and Interpretation
Ticagrelor is an adenosine-like molecule, which may act as a promoter of blood adenosine, serving as adenosine agonist. Furthermore, ticagrelor may increase adenosine concentrations, whereas preclinical data in dogs showed both ticagrelor and dipyridamole to augment reactive hyperemia in a dose-dependent manner after LAD occlusion and the intracoronary adenosine-induced increases in LAD blood flow. 5 A higher availability of adenosine while on treatment with ticagrelor rather than on prasugrel is therefore very likely and may account for the increased CBFV responsiveness to adenosine administered exogenously. The platelet ADP P2Y12 receptors, which are the target for both ticagrelor and prasugrel, are also found on vascular smooth muscle cells where they mediate arterial contraction. 12 In bench studies, high doses of oral clopidogrel treatment had no inhibitory effect, whereas ticagrelor added ex vivo inhibited P2Y12-mediated vasoconstriction in murine vessels, human internal mammary arteries, and small human arteries. 13 In a dog thrombosis model, animals treated with ticagrelor had significantly lower rates of reocclusion, less cyclic flow variation, and longer reflow duration compared with animals treated with clopidogrel, despite similar antiplatelet effects.
14 In a rat model, ticagrelor, in contrast to clopidogrel and prasugrel, prevented ATP-induced contraction of vascular smooth muscle cells. 15 Our results are in the same line of evidence. These effects of ticagrelor, regardless of the mediating mechanism (adenosine action, different than the thienopyridines binding site, reversibility), might be particularly beneficial in the management of conditions in which vasospasm may be involved. Before adenosine infusion, there were no differences in CBFV between ticagrelor-and prasugrel-treated patients. It seems, therefore, that it is only during the exposure to the potent vasodilatory action of adenosine infusion when their differences become apparent. Similarly, compared with placebo, neither ticagrelor nor placebo affected basal CBFV before adenosine infusion. 7 The differences in maxCBFV/ bCBFV in favor of ticagrelor were apparent at all, but not the highest adenosine infusion rate. This most likely reflects the fact that at the highest used adenosine infusion rate, a maximal coronary vasodilation is expected to occur in the majority of the patients, irrespective of the presence or absence of an adjunctive or auxiliary vasodilatory action.
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Ticagrelor Versus Prasugrel Comparison: Possible Clinical Relevance
The previously published head-to-head comparisons of ticagrelor versus prasugrel have been only pharmacodynamic ones comparing their antiplatelet action, without the power to assess any differences in outcome. [18] [19] [20] So far, no direct clinical comparison of ticagrelor versus prasugrel has been performed.
In the PLATO trial, hypotheses were raised that the mechanisms of the beneficial effect observed with ticagrelor might be beyond its antiplatelet action. The reason of lowering total and cardiovascular mortality with ticagrelor remains unclear. It was hypothesized that modulation of adenosine receptors might play an important role. 3, 4 Although there is no direct clinical relevance, the enhancement of adenosine-induced increase in CBFV demonstrated in the present study may represent an off-target cardiovascular effect of ticagrelor, possibly contributing to its beneficial effects seen in the PLATO trial. Other features observed in patients with ST-elevation ACS in the PLATO trial, such as the accruing reduction in secondary efficacy end points over time and the continuing separation of event curves beyond the first month and during long-term treatment, have been attributed to possible adenosine-like actions of ticagrelor. 21 Apart from the beneficiary effects, adverse events, such as bradycardia and dyspnea, have also been associated with ticagrelor but not prasugrel treatment. These have been attributed to increased extracellular adenosine levels caused by ticagrelor, although adenosine hypothesis as the cause of dyspnea has been recently disputed.
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Limitations
The main limitation of our study is that adenosine levels were not measured, and therefore the observed differences cannot be considered causative. The reversibility of the adenosinemediated CBFV response by theophylline was not assessed.
However, this has been previously demonstrated to occur in healthy volunteers. 7 Because of the lack of a placebo group, a pleiotropic action for prasugrel cannot be excluded with absolute certainty. However, no possibility that such action may exist has been raised so far. Our results apply to a shortterm interval after PCI. Similar possible actions of long-term administration of ticagrelor or prasugrel have not been studied. We did not use low dose of an intravenous contrast for improved color Doppler signal and spectral Doppler signals in the LAD. However, ultrasonographic assessment of the CBFV seems very feasible, reproducible, and accurate in experienced hands, even without contrast agent injection, and is favorably compared with that obtained with invasive Doppler flow wire.
Conclusions
In NSTE-ACS patients treated with PCI and receiving maintenance dose of ticagrelor, CBFV augments to a greater degree compared with those on prasugrel maintenance dose, in response to incremental doses of adenosine. Although these results are exploratory, they may represent a pleiotropic action of ticagrelor potentially associated with some of the clinical benefits provided by this agent. 
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